Scarica l'app Stockscreener
2.85
2.15%
0.06
Precedente Chiudi:
$2.79
Aprire:
$2.81
Volume 24 ore:
211.65K
Relative Volume:
0.70
Capitalizzazione di mercato:
$123.18M
Reddito:
-
Utile/perdita netta:
$-110.66M
Rapporto P/E:
-0.9205
EPS:
-3.0963
Flusso di cassa netto:
$-97.76M
1 W Prestazione:
+11.76%
1M Prestazione:
+25.00%
6M Prestazione:
-42.42%
1 anno Prestazione:
-78.03%
Intervallo 1D:
$2.745
$2.885
Intervallo di 1 settimana:
$2.47
$2.885
Portata 52W:
$1.78
$16.64
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Nome
Kyverna Therapeutics Inc
Settore
Industria
Telefono
(510) 626-8331
Indirizzo
5980 HORTON STREET, EMERYVILLE
Confronta KYTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
2.85 | 110.21M | 0 | -110.66M | -97.76M | -3.0963 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-27 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-10-10 | Iniziato | UBS | Buy |
| 2024-10-09 | Iniziato | Rodman & Renshaw | Buy |
| 2024-07-03 | Iniziato | H.C. Wainwright | Neutral |
| 2024-03-04 | Iniziato | JP Morgan | Overweight |
| 2024-03-04 | Iniziato | Leerink Partners | Outperform |
| 2024-03-04 | Iniziato | Morgan Stanley | Overweight |
| 2024-03-04 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Kyverna Therapeutics Inc Borsa (KYTX) Ultime notizie
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Millennium Management LLC - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Short Interest Up 20.6% in May - MarketBeat
Kyverna Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Ameriprise Financial Inc. Raises Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace
Kyverna Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX - ACCESS Newswire
Kyverna, Rocket, Teva, Fair Isaac, Oklo Trending by Analysts - TipRanks
Northern Trust Corp Purchases 61,757 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to "Buy" at HC Wainwright - MarketBeat
Kyverna Therapeutics to Present at the Jefferies Global Healthca - GuruFocus
Autoimmune Cell Therapy Pioneer Kyverna Therapeutics Takes Stage at Major Jefferies Conference - Stock Titan
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Kyverna Therapeutics’ KYV-101: Promising Developments and First-to-Market Potential in Autoimmune Diseases - TipRanks
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to “Buy” at HC Wainwright - Defense World
With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around? - Benzinga
Kyverna Therapeutics Shares Rise After Upgrade From HC Wainwright - marketscreener.com
HC Wainwright & Co. Upgrades Kyverna Therapeutics (KYTX) - Nasdaq
Kyverna Therapeutics: Buy Rating Backed by Promising Pipeline and Strong Financial Position - TipRanks
HC Wainwright Upgrades Kyverna Therapeutics to Buy From Neutral, Adjusts Price Target to $5 From $4 - marketscreener.com
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
HC Wainwright Issues Pessimistic Estimate for KYTX Earnings - MarketBeat
Analysts Offer Predictions for KYTX Q1 Earnings - MarketBeat
HC Wainwright Issues Pessimistic Outlook for KYTX Earnings - Defense World
Analysts Issue Forecasts for KYTX Q1 Earnings - Defense World
Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of “Buy” by Analysts - Defense World
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. LawsuitKYTX - ACCESS Newswire
Jacobs Levy Equity Management Inc. Buys 442,090 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Sphera Funds Management LTD. - MarketBeat
Integral Health Asset Management LLC Purchases 150,000 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Leerink Partnrs Has Positive Outlook of KYTX Q2 Earnings - Defense World
Stifel Financial Corp Buys New Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff - BioPharma Dive
KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Kyverna Shareholder Sues Over Kidney Therapy Trial Data Post IPO - Bloomberg Law News
Kyverna planning to launch Phase 3 trial of KYV-101 in MG patients - Myasthenia Gravis News
With 40% ownership, Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has piqued the interest of institutional investors - Yahoo Finance
Kyverna lays off 16% of staff as autoimmune CAR-T plans pick up pace - Fierce Biotech
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases - Seeking Alpha
Kyverna Therapeutics Provides Business Update And Reports First Quarter 2025 Financial Results - marketscreener.com
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results - PR Newswire
Kyverna's Autoimmune Pipeline Hits Major Milestones: SPS Trial Full, MG Phase 3 Gets FDA Green Light - Stock Titan
Kyverna Therapeutics (KYTX) Projected to Post Quarterly Earnings on Tuesday - Defense World
KYTX Stockholders Have Opportunity to Lead Kyverna Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Barclays PLC Acquires 19,419 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - ACCESS Newswire
Kyverna Therapeutics (KYTX) to Release Quarterly Earnings on Tuesday - MarketBeat
Kyverna Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX - ACCESS Newswire
Kyverna Therapeutics Inc expected to post a loss of $1.11 a shareEarnings Preview - TradingView
Class Action Filed Against Kyverna Therapeutics, Inc. (KYTX)February 7, 2025 Deadline to Join – Contact Levi & Korsinsky - ACCESS Newswire
Marshall Wace LLP Decreases Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Kyverna Therapeutics Inc Azioni (KYTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
0.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):